The compounding effects from floods, storm surge, and terrestrial flooding (rivers) are projected to increase due to global warming.There is currently no consensus on how climate change will affect the overall frequency of tropical cyclones. A majority of climate models show a decreased frequency in future projections. For instance, a 2020 paper comparing nine high-resolution climate models found robust decreases in frequency in the Southern Indian Ocean and the Southern Hemisphere more generally, while finding mixed signals for Northern Hemisphere tropical cyclones. Observations have shown little change in the overall frequency of tropical cyclones worldwide, with increased frequency in the North Atlantic and central Pacific, and significant decreases in the southern Indian Ocean and western North Pacific. There has been a poleward expansion of the latitude at which the maximum intensity of tropical cyclones occurs, which may be associated with climate change. In the North Pacific, there may also have been an eastward expansion. Between 1949 and 2016, there was a slowdown in tropical cyclone translation speeds. It is unclear still to what extent this can be attributed to climate change: climate models do not all show this feature. Observation and forecasting
Observation
Intense tropical cyclones pose a particular observation challenge, as they are a dangerous oceanic phenomenon, and weather stations, being relatively sparse, are rarely available on the site of the storm itself. In general, surface observations are available only if the storm is passing over an island or a coastal area, or if there is a nearby ship.
However, it did find a 62% decrease in COVID-19–related medical visits (p=0.023), which was consistent with the 67% reduction from the EPIC-HR (high-risk patients) study. Pfizer discontinued enrollment in the study because of the low rate of hospitalization and death in this population. Society and culture
Legal status
On 16 November 2021, Pfizer submitted an application to the US Food and Drug Administration (FDA) for emergency use authorization for the co-packaged medication. The authorization was granted on 22 December 2021, for adults and children ages 12 and older who are infected with Covid and at risk. The European Medicines Agency (EMA) issued guidance about the use of the co-packaged medication for the treatment of COVID-19 in the EU on 16 December 2021. The Israeli Ministry of Health approved the use of the co-packaged medication on 26 December 2021. South Korea approved the use of the co-packaged medication on 27 December 2021.The UK Medicines and Healthcare products Regulatory Agency (MHRA) granted conditional approval of the co-packaged medication in December 2021. Health Canada approved the use of the co-packaged medication in January 2022. The Singapore Health Sciences Authority approved the use of the co-packaged medication for treating adults in February 2022. In February 2022, China approved the medication for the treatment of adults who have mild to moderate COVID-19 and are at a high risk of progressing to a severe condition. Economics
In December 2021, the German government ordered 1 million doses of, but by August 2022, only around 43,000 had been delivered by wholesalers to pharmacies.